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OBJECTIVE—The agouti-related protein (Agrp) is a powerful
orexigenic peptide, but little is known about its transcriptional
regulation. The objective of this study was to determine molec-
ular mechanisms for the activation of hypothalamic Agrp and
identify compounds that stimulate appetite.
RESEARCH DESIGN AND METHODS—We used promoter
analyses methods, hypothalamic cell culture and transfection,
immunohistochemistry, luciferase-expressing transgenic mice, in
vivo bioluminescence, anitisense RNA, mouse feeding studies,
indirect calorimetry, real-time PCR, and Western blots.
RESULTS—We found that the Kru ¨ppel-like factor 4 (Klf4) is a
potent activator of Agrp by binding to a speciﬁc CACCC-box in
its minimal promoter. We also found that an extract of tarragon,
termed PMI-5011, activated hypothalamic Klf4 and Agrp. In vivo,
PMI-5011 increased Agrp promoter activity in luciferase-express-
ing transgenic mice, increased hypothalamic Klf4 and Agrp
expression, increased hypothalamic Orexin and melanin-concen-
trating hormone, increased food intake, reduced circulating
insulin and leptin levels, attenuated energy expenditure, and
enhanced body weight but only when using a high-fat diet.
CONCLUSIONS—These data show that Klf4 augmented hypo-
thalamic Agrp by binding to a speciﬁc CACCC-box onto its
minimal promoter. In addition, the tarragon extract PMI-5011
activated Klf4 and orexigenic neuropeptides and reduced periph-
eral insulin and leptin levels leading to positive energy balance.
Diabetes 60:97–106, 2011
T
he orexigenic agouti-related protein (AgRP) neu-
ropeptide is expressed in neurons that are essen-
tial in adult mice for the regulation of energy
homeostasis (1,2), and its overexpression leads
to increased food intake (3). We have shown that the
noncoding exon of AGRP has signiﬁcant promoter activity
and is sufﬁcient to drive expression in various tissues
(4–6), whereas others have reported binding sites for
FOXO1 and STAT3 (7). AGRP polymorphisms in humans
have been associated with leanness and food preference
(8–10), but little is known about its transcriptional regu-
lation (11).
In the present study, we set out to determine molecular
mechanisms for the activation of AgRP. Bioinformatic
analysis of the minimal promoter of the human AGRP gene
identiﬁed putative binding sites for the zinc ﬁnger Kru ¨ppel-
like factor 4 (KLF4) (aliases GKLF and EZF) that binds to
canonical CACCC-box motifs (12–15). Klf4 is one of the
four essential transcription factors that induce pluripotent
stem cells from adult ﬁbroblasts (16) and can also act as a
proto-oncogene in breast cancer (17), whereas its deletion
leads to embryonic death as a result of water loss across
the skin surface (18). Klf4, thus, became a candidate
transcription factor for the regulation of AGRP.
In addition, we aimed to identify bioactive compounds
that activate AGRP and stimulate appetite. We tested a
range of botanical extracts from green tea, berries, and
other botanicals and found that an extract of Russian
tarragon (Artemisia dracunculus L.), termed PMI-5011,
enhanced food intake in a complex manner that involved
activation of orexigenic neuropeptides and attenuation of
insulin and leptin. According to ancient folklore, tarragon
was used by Greeks and Persians as an appetite stimulant
and a digestive aid (19) and is still used today in culinary
French cuisine. Its physiological effects, however, are
multifaceted. Puriﬁed extracts of Russian tarragon, and
speciﬁcally PMI-5011, have been shown to have antihyper-
glycemic effects and to reduce insulin and glucose levels in
streptozotocin-induced diabetic mice (20), whereas others
have shown that it has anticarcinogenic properties (21).
Here, we report the molecular mechanism for the acti-
vation of Agrp by Klf4 and describe the wider effects of the
tarragon extract PMI-5011 on Agrp, Klf4, the overall orexi-
genic circuitry, and hormones involved in the maintenance
of energy homeostasis.
RESEARCH DESIGN AND METHODS
PMI-5011 preparation. PMI-5011 is a bioactive extract of Russian tarragon
(Artemisia dracunculus L.) consisting of six potential components (22). It
was prepared as previously described from hydroponically grown plants and
puriﬁed as a resin (19,20,23).
Cell culture and reagents. The human adrenocortical carcinoma cell line
NCI-h295R (American Type Culture Collection, Manassas, VA) and mouse
neuronal N38 (24) and GT1-7 (25) cell lines were cultured as previously
described (26). PMI-5011 was dissolved in 70% ethanol or DMSO and added to
the media at the concentration of 40 g/ml.
Whole brain primary cell cultures. Two whole mouse brains were removed
and transferred immediately into 7 ml of dissection media (500 ml Hank’s
buffered salt solution; Invitrogen, Carlsbad, CA), 1.19 g HEPES, 2.52 g glucose,
50 l gentamicin (Invitrogen), 1.5 g BSA (Sigma, St. Louis, MO), 1.5 g Mg2SO4,
and 111 mg CaCl2. Cells were dissociated and gradually attached to the
bottoms of culture plates reaching 90% conﬂuency in 10–12 days.
AGRP promoter constructs. A 1,107-bp AGRP promoter fragment (796/
312) was ampliﬁed from human genomic DNA with Platinum Pfx polymerase
(Invitrogen) using the PCR primers 5-GTCAGCTAGCGTCTTAAACCCCTGGC
CTTG-3 and 5-CAGTCTCGAGCCTTGGAGTCCCCTCTAGG-3. Amplicons was
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diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 97digested with NheI/MluI and cloned into the pGL3basic luciferase vector (Pro-
mega, Madison, WI). Site-directed mutagenesis was performed as described in
line n the supplementary data in the online appendix (available at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0172/DC1). The numbering of DNA se-
quence cited in this manuscript (e.g., for the CACCC-box) was according to the
sequence appearing in our previous publication (5) and GenBank accession no.
AF314194.
Transient transfections. Cells were transfected with Geneporter II (Gene
Therapy Systems, San Diego, CA) or Fugene 6 according to the manufacturer’s
protocols. Fireﬂy and renilla luciferase activities were measured using the
Dual Luciferase Kit (Promega) and a single-tube FB12 luminometer (Berthold
Detection Systems, Oak Ridge, TN). More details about the constructs are
provided on line in the supplementary data.
Electrophoretic mobility shift assays. Nuclear extracts from N38 cells
were prepared as described elsewhere (27). A complete list of the oligonu-
cleotides used is shown on line in the supplementary data.
Chromatin immunoprecipitation. NCI-h295R human adrenocortical cells
were cultured in a 100-mm cell culture plate and transfected with KLF4-
expressing vector or cotransfected with KLF4 and 796/373 AGRP pro-
moter construct for 16 h. The experimental procedure was according to the
manufacturer’s instructions (Upstate, Millipore, Billerica, MA). More details
about the primers and conditions are provided on line in the supplementary
data.
RNA extraction and real-time PCR. Total RNA was extracted from
cultured cells or whole tissue using the RNeasy Mini Kit (Qiagen). Hypotha-
lamic extracts were prepared as previously described (26). Quantitative PCR
was performed using the TaqMan one-step RT-PCR core reagents kit (Applied
Biosystems, Foster City, CA) as previously described (28). The primers and
probes are described in detail on line in the supplementary data.
Western blotting. For Western blot analysis, total protein lysates (30–50
g/lane) were separated on 15% or 10% SDS-PAGE and blotted to Immun-Blot
polyvinylidene diﬂuoride membranes (Bio-Rad, Hercules, CA). Antibodies for
Agrp were from Alpha Diagnostic International (San Antonio, TX) and Klf4
from Santa Cruz Biotechnology (Santa Cruz, CA). For loading control anti–
glyceraldehyde-3-phosphate dehydrogenase (AM4300; Ambion) or -actin
(Abcam, Cambridge, MA) antibody were used. The signal was detected with
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FIG. 1. Klf4 overexpression increased Agrp in GT1-7 cells, whereas overnight food deprivation augmented hypothalamic Agrp and Klf4. A: The
minimal promoter of AGRP contains two CACCC-boxes (underlined) that are putative bindings sites for KLF4 (proximal [A] and distal [B]). B:
Transient transfection of hypothalamic GT1-7 cells with a KLF4 expression construct increased AGRP mRNA and (D) Agrp protein levels. C and
E: KLF4 overexpression also increased endogenous Agrp mRNA and protein levels in mouse whole-brain primary cultures from two male mice,
respectively. F: Immunocytochemistry of dividing GT1-7 hypothalamic cells displaying elevated Klf4 and Agrp protein levels. G: Transiently
transfected GT1-7 cells with a KLF4 expression construct displayed accumulation of KLF4 in the nucleus (arrows) and overexpression of endogenous
Agrp. Hypothalamic Agrp mRNA (H) and Klf4 mRNA (I) were signiﬁcantly increased in mice that were food deprived overnight (n  6 fed mice, n 
7 food-deprived mice). AU, arbitrary units representing Klf4 or Agrp mRNA levels adjusted by cyclophilin mRNA as endogenous control. Data are
shown as means  SE (*P < 0.05; **P < 0.01). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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inghamshire, U.K.). Western blot images were quantiﬁed using Quantity One
software (Bio-Rad).
Immunoﬂuorescence. GT1-7 cells were plated on 12-mm glass coverslips
coated with poly-D-lysine. Cells were washed in PBS and ﬁxed in 4%
paraformaldehyde. Immunocytochemistry was performed using Klf4 and Agrp
antibodies (dilution 1:200) in a cocktail. This was followed by three washes in
the presence of a secondary Alexa Fluor 488 goat anti-rat antibody and Alexa
Fluor 594 goat anti-rabbit antibody (Invitrogen, Eugene, OR). Finally, slides
were mounted in Prolong Gold Antifade Reagent with 4,6-diamidino-2-
phenylindole (Invitrogen). Microphotographs of stained cells were taken with
a Axioscop 2 microscope (Zeiss) at 40 magniﬁcation. Color images were
captured with a Zeiss Axiocam HRc CCD camera at 1,300  1,030 resolution.
In vivo bioluminescence. In vivo bioluminescence imaging was conducted
on an IVIS 100 system (Xenogen, Alameda, CA) using LivingImaging acquisi-
tion and analysis software (Xenogen). The rationale for the production of
these mice and a full description of the constructs used is provided elsewhere
(6). The mice used in this experiment contained the Klf4-binding CACCC-box
and additional enhancer elements from downstream regions. Mice were
anesthetized with isoﬂurane and received an intraperitoneal injection of the
substrate D-luciferin (100 mg/kg). An integration time of 3 min with a binning
of 100 pixels was used for luminescence image acquisition. Signal intensity
was quantiﬁed as the sum of all detected photon counts within the region of
interest after subtraction of background luminescence. Mice were fed chow
diet (Chow 5001, 12.5% Kcal, Purina lab diet; Framingham, MA) ad libitum and
imaged the day before the start of feeding with PMI-5011 and imaged again 1
week later, at the end of the experiment.
Indirect calorimetry. The study protocols for all mouse feeding studies were
approved by the institutional animal care and use committee of the Penning-
ton Biomedical Research Center (Louisiana State University System, Baton
Rouge, LA). Mice were maintained on a 12-h/12-h day/light cycle in a
pathogen-free animal facility with lights coming on at 6:00 A.M. Indirect
calorimetry was performed as we have previously described (29). More details
are provided on line in the supplementary online data.
Body composition. Fat-free body ﬂuid and fat-free mass were measured with
a nuclear magnetic resonance instrument (Bruker Optics, The Woodlands,
TX) as we have previously reported (29). Fat-free mass (i.e., muscle mass) was
calculated by subtracting the fat mass and ﬂuid mass from total body weight.
Data are shown as means of grams of fat or grams of lean mass.
Mouse feeding studies with PMI-5011. Several mouse-feeding studies were
performed using chow and high-fat diets (HFDs) with and without PMI-5011.
Details about each study are provided on line in the supplementary data.
Statistical analyses. Statistical signiﬁcance was evaluated using one-way
ANOVA and the Student t test. The data were expressed as means  SE and
calculated using variance analysis and the Newman-Keuls test for multiple
comparisons among groups. Bonferroni adjustments were made for multitest-
ing. P values 	0.05 were considered to be statistically signiﬁcant. The same
methods were used for testing for differences in circulating hormone levels.
Data analysis was carried out on SAS (SAS version 9.1).
For the meta-analysis, the data from the three HFD studies were combined
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FIG. 2. AGRP promoter analysis showed KLF4 speciﬁcity for the proximal CACCC-box. A: Mutagenesis of the proximal (mutA) but not the distal
(mutB) CACCC-box signiﬁcantly diminished the effect of KLF4 on AGRP promoter activity in transiently transfected clonal hypothalamic N38
cells. B: Mutagenesis of the proximal (mutA) but not the distal (mutB) CACCC-box completely abrogated the effect of KLF4 on AGRP promoter
activity in transiently transfected human adrenocarcinoma NCI-h295R cells. C: Sp1 did not increase AGRP promoter activity on its own or when
cotransfected with KLF4, whereas mutagenesis of the proximal CACCC-box (mutA) abrogated the effect of KLF4 on its own or in combination
with Sp1. D: EMSA experiments using wild-type (Wt) and mutant (mutA) competition (Compet) primers. E: Antibody-supershift EMSA conﬁrmed
that Klf4 directly bound the promoter of AGRP at the proximal CACCC-box (mutA). Nuclear extracts (NE) were obtained from clonal
hypothalamic N38 cells transfected either with the empty-vector pcDNA3.1 (P) or the KLF4 expression vector (K). The position of the
KLF4-containing protein complex is marked by an arrow. Basic transcription element (BTE) corresponds to a known KLF4 binding site as the BTE
of the CYP1A1 gene (30), as a positive control. F: Chromatin immunoprecipitation (ChIP) assays, using lysates from KLF4-transfected cells
(second bar) or cells cotransfected with a combination of KLF4 and AGRP796/373 promoter. Increased immunoprecipitates were found in
the cotransfected cells because of enrichment for the CACCC-box (RLA, relative luciferase activity adjusted by renilla). Data are shown as
means  SE (*P < 0.05; **P < 0.01; ***P < 0.001).
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weight between the HFD- and PMI-5011–fed groups. The random effects
ANOVA meta-analysis model was used. The results represent the unweighted
ANOVA analysis. The ANOVA analysis in a bootstrap fashion was also used,
and again the P value was nearly identical. Data analysis was carried out on
SAS (SAS version 9.1).
Nomenclature. The gene names used were according to standard nomencla-
ture (http://www.genenames.org/ and http://www.informatics.lax.org/mglhome/
nomen/gene.shtml).
RESULTS
Overexpression of Klf4 activated endogenous Agrp in
hypothalamic cells. Algorithmic analysis of the human
AGRP promoter (Tess/Transfac and Alibaba2) revealed
the presence of two conserved CACCC-boxes at position
163/169 (position A or proximal position), and position
277/283 that is a reverse CACCC-box/G-rich stretch
(position B or distal position) (Fig. 1A). CACCC-boxes are
typical binding motifs for the transcription factor KLF4
(12–15), which became a candidate effector of AGRP. The
direct effect of KLF4 on Agrp was tested by transiently
transfecting GT1-7 cells with a KLF4 expression con-
struct, which resulted in an increase of endogenous Agrp
mRNA and protein levels (Fig. 1B and D, respectively).
This effect was recapitulated in mouse whole-brain pri-
mary cultures from two male mice (Fig. 1C and E).
Immunocytochemistry was performed to determine the
speciﬁcity of the effect of KLF4 on Agrp expression.
Endogenous Klf4 protein was upregulated in dividing
GT1-7 cells, which coincided with signiﬁcant upregulation
of Agrp (Fig. 1F). Cells that had been successfully trans-
fected with a KLF4 expression construct displayed signif-
icant accumulation of KLF4 in the nucleus and robust
upregulation of Agrp (Fig. 1G), suggesting that KLF4
directly enhances endogenous Agrp expression in hypo-
thalamic cells.
Overnight food deprivation increased hypothalamic
Agrp and Klf4 expression. We assessed the effects of
overnight food deprivation on mouse hypothalamic Klf4
and Agrp and found that both were upregulated in mRNA
preparations (Fig. 1H and I).
KLF4 binds to a speciﬁc CACCC-box on the AGRP
promoter. The effect of KLF4 on the AGRP promoter was
evaluated by site directed mutagenesis of the two candi-
date CACCC-boxes at positions A and B. The mouse clonal
hypothalamic cell line (N38) and the human adrenocorti-
cal carcinoma cell line NCI-h295R were used for these
experiments because they both express endogenous Agrp
whereas the NCI-h295R cell line also represents a “human”
environment because we are using the human AGRP
promoter. Mutagenesis of the proximal (position A or
mutA) but not the distal CACCC-box (mutB) diminished
signiﬁcantly the effect of KLF4 on AGRP promoter in the
mouse N38 (Fig. 2A) and completely abolished promoter
activity in the human environment of the NCI-h295R cells
(Fig. 2B). Because KLF4 had been suggested to interact
with the Sp1 family of transcription factors (30), we used
a Sp1 expression construct but found that it had no effect
on AGRP promoter activity, and neither did it enhance the
effect of KLF4 (Fig. 2C).
Electrophoretic mobility shift assays (EMSAs) revealed
a complex binding pattern for vector control (P) and a
speciﬁc band (arrow) in KLF4 (K)-transfected cells (Fig.
2D). Preincubation with excess unlabeled wild-type probe
competed out this band in the KLF4-transfected cells
(lane 6) but not with the mutant probe (lane 7), further
emphasizing the signiﬁcance of the intact CACCC-box at
position A. Importantly, the complex of interest could be
completely competed away with a known KLF4 binding
oligonucleotide from the cytochrome CYP1A1 gene (30)
referred to in this ﬁgure as “BTE” (Fig. 2D, lane 8). The
radiolabeled mutant probe (mutA) did not result in the
appearance of the additional band after incubation with
the KLF4-transfected nuclear extracts (Fig. 2D, lanes
9–15).
In an EMSA supershift experiment, speciﬁc antibodies
were used to identify the band of interest (Fig. 2E). Again,
only KLF4 cotransfected extracts (K) resulted in the
formation of an additional band (Fig. 2E, lane 4). Binding
was completely blocked with an anti-Klf4 antibody (Fig.
2E, lane 5) but not with the negative control antibody
directed against Sp1 (Fig. 2E, lane 6). The mutant probe
again failed to form any Klf4-speciﬁc DNA:Protein com-
plexes (Fig. 2E, lanes 7–12).
In chromatin immunoprecipitation (ChIP) experiments,
the human NCI-h295R cells were transiently transfected
ﬁrst with the KLF4 expression construct, and in a second
experiment they were cotransfected with the KLF4 ex-
pression construct plus the AGRP 796/312 promoter
construct. The second experiment represented a positive
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FIG. 3. PMI-5011 activated the AGRP promoter in vitro and in vivo. A:
PMI-5011 treatment of GT1-7 cells that had been transiently trans-
fected with a construct containing the minimal promoter of AgRP
PMI-5011, displayed signiﬁcant increase of promoter activity. The data
shown are the mean of three independent experiments, each experi-
ment represented by three replicates (SE). B: Feeding luciferase-
expressing transgenic mice with diet supplemented with PMI-5011 for
1 week, led to a sixfold increase of luciferase that was driven by the
minimal promoter of AgRP. The left panel in all images shows two mice
from founder A and the right panel shows two mice from founder B.
Luciferase expression was measured as the total number of pixels
using the IVIS 100 software (***P < 0.001). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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KLF4-binding CACCC-box. The coimmunoprecipitate
from the ﬁrst experiment was higher in the KLF4-trans-
fected cells and this effect was further enhanced in the
promoter cotransfected cells from the second experiment
that had been enriched for the CACCC-box (Fig. 2F).
PMI-5011 activated the AGRP promoter in vitro and
in vivo. We tested the hypothesis that a botanical extract
of tarragon, PMI-5011, could activate Agrp because tarra-
gon has traditionally been used as an appetite stimulant.
First, we tested the hypothesis that PMI-5011 activates
Agrp at the promoter level in vitro. GT1-7 cells were
transient transfection with a promoter construct contain-
ing the minimal promoter of AGRP and cells were treated
overnight with PMI-5011. The activity of the AGRP pro-
moter (796/373) was signiﬁcantly increased by PMI-
5011 (Fig. 3A). We then tested the hypothesis that PMI-
5011 also activates the AGRP promoter in vivo. We used
luciferase-expressing transgenic mice whereby luciferase
was driven by the minimal promoter of AGRP that encom-
passes the proximal CACCC-box at position 163/169,
as we have described elsewhere (6). Two mice from two
different founders were imaged while consuming a chow
diet (Fig. 3B). Their diet was subsequently supplemented
with PMI-5011 for 1 week, and the same mice were imaged
again. Luciferase expression was increased sixfold by
PMI-5011 in mice from both founders and at all sites of
expression as illustrated by the ventral and dorsal views
(Fig. 3B).
Silencing of Klf4 abrogated the activation of Agrp by
PMI-5011. In this experiment, we tested the hypothesis
that Klf4 mediates the activation of Agrp by PMI-5011.
First, we showed that PMI-5011 activated both endoge-
nous Agrp and Klf4 in GT1-7 cells (Fig. 4A and B, respec-
tively). The speciﬁc requirement of Klf4 for the activation
of Agrp by PMI-5011 was conﬁrmed using antisense siRNA
probes against Klf4. First, the efﬁcacy of siRNA primers
against Klf4 was conﬁrmed in GT1-7 cells by blocking the
upregulation of Klf4 in cells treated with PMI-5011 (Fig.
4C), whereas the control (scrambled) primers had minimal
effect. siRNA against Klf4 also abrogated the upregulation
of Agrp by PMI-5011 (Fig. 4D).
PMI-5011 increased endogenous Klf4 and Agrp, stim-
ulated food intake, and reduced energy expenditure.
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body composition were evaluated by indirect calorimetry
in metabolic chambers. Two groups of mice of equal mean
body weights received chow or chow plus PMI-5011 diets,
and metabolic parameters were measured for 4 days.
Hypothalamic Klf4 and Agrp protein levels were signiﬁ-
cantly higher in the PMI-5011 group (Fig. 5A). Body weight
and body composition (fat and fat-free mass) were not
affected by PMI-5011 (Fig. 5B and C), but food intake was
signiﬁcantly higher (Fig. 5D). Oxygen consumption and
energy expenditure (heat production) were signiﬁcantly
lower in the PMI-5011–fed group (Fig. 5E and F). The
Respiratory exchange ratio (RER) and total activity were
not affected by PMI-5011 (Fig. 5G and H).
PMI-5011 increased Agrp, food intake, and body
weight under a HFD. Because body weight was not
increased as it would be expected given the increased food
intake and reduced energy expenditure, another study was
performed to examine the long-term (24-day) effects of
PMI-5011 on food intake still under a chow diet. Hypotha-
lamic Klf4 and Agrp protein levels, as well as total food
intake, were signiﬁcantly higher in the PMI-5011–fed group
of mice (Fig. 6A and B), but body weight was again
unaffected (data not shown). We then examined the hy-
pothesis that a higher fat content may be required to be
present in the diet for effects of PMI-5011 to become
evident on body weight. We examined the data from three
previously performed studies that had used PMI-5011 in a
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PMI-5011 was enhanced in all three studies and both Agrp
and Klf4 were signiﬁcantly elevated (Fig. 6C). A meta-
analysis was then performed using the data from all three
studies that showed a statistically signiﬁcant increase for
the overall body weight of mice consuming HFD supple-
mented with PMI-5011 (Fig. 6D).
PMI-5011 reduced circulating levels of leptin and
insulin. We measured the effects of PMI-5011 on the
circulating levels of hormones known to affect Agrp ex-
pression and energy balance: insulin, leptin, ghrelin (ac-
tive), peptide tyrosine tyrosine (PYY) (total), and gastric
inhibitory polypeptide or glucose-dependent insulino-
tropic peptide (GIP) (total). In this experiment, C57BL/6
male mice were fed ad libitum HFD or HFD plus PMI-5011
for 11 days. PMI-5011 was provided by gavage. Insulin and
leptin were signiﬁcantly lower in the PMI-5011 group (Fig.
7A and B) but ghrelin, PYY, and GIP were not signiﬁcantly
affected (Fig. 7C–E).
PMI-5011 stimulated Mch and Orexin expression. In
addition to Agrp, the expression levels of other orexigenic
and anorexigenic neuropeptides were measured in the
hypothalami of control and PMI-5011 chow-fed mice that
had been used in the metabolic chambers. Overall, hypo-
thalamic Agrp mRNA levels were increased in the PMI-
5011 group (Fig. 8A), and this effect was more pronounced
in four of seven mice (i.e., high responders P 	 0.05, not
shown here). Neuropeptide Y (Npy) mRNA levels were not
signiﬁcantly affected by PMI-5011 (Fig. 8B), but the mRNA
levels of the other orexigenic peptides, Orexin and Mch,
were signiﬁcantly higher in the PMI-5011 group (Fig. 8C
and D). The mRNA levels of the anorexigenic peptides
Pomc and Cart were not signiﬁcantly affected by PMI-5011
(Fig. 8E and F).
DISCUSSION
In the present study, we investigated the effects of a
bioactive extract of tarragon, PMI-5011, on appetite stim-
ulation. Agrp was our primary target because of it is a
well-characterized appetite effector (10,11,31). We found
that PMI-5011 signiﬁcantly upregulated the promoter of
the human AGRP gene and increased its expression levels
in neuroblastoma cells as well as in mouse hypothalamic
primary cell cultures. A landmark feature of hypothalamic
Agrp is its upregulation by food deprivation (3,26,32). We
found that Klf4 was also upregulated by overnight food
deprivation. This suggests that the two genes may be
coregulated. We do not know if Klf4 upregulation precedes
that of Agrp, which would enhance the notion that it may
be involved in the upregulation of Agrp by food depriva-
tion in vivo. Further experiments would be required to
conﬁrm this possibility.
Using bioinformatics tools, KLF4 was identiﬁed as a
candidate transcription factor for the activation of AGRP
because of the presence of conserved CACCC-boxes along
its promoter, which are typical binding motifs for KLF4
(33,34). PMI-5011 was found to augment both Klf4 and
Agrp protein levels, whereas transient transfections of
cells with a KLF4 expression construct conﬁrmed the
direct stimulation of Agrp. Further experiments using
*
*
Ctr 5011
α-Agrp
α-Gapdh
α-Klf4
α-Gapdh
62
64
66
68
70
72
74
76
78
Chow 5011
T
o
t
a
l
 
F
o
o
d
 
i
n
t
a
k
e
 
(
g
)
* B
A
α-Agrp
α-Gapdh
α-Klf4
α-Gapdh
*
Ctr 5011
*
0
2
4
6
8
10
12
14
16
HFD-1 HFD-2 HFD-3
B
o
d
y
 
w
e
i
g
h
t
 
c
h
a
n
g
e
 
(
g
)
HFD
HFD + 5011
P = 0.025 (Meta-analysis) D
C
FIG. 6. PMI-5011 increased Agrp/Klf4 and food intake, but body weight was increased only under an HFD. A: Agrp and Klf4 protein levels were
signiﬁcantly higher in the group receiving PMI-5011 in a chow diet for 24 days. n  6 in the chow diet group and n  7 in the chow diet plus
PMI-5011 group. B: Total food intake was signiﬁcantly higher in the PMI-5011–fed group. C: Agrp and Klf4 protein levels were signiﬁcantly higher
in the mice receiving PMI-5011 in HFD (data shown for HFD-1). D: Meta-analysis of the combined HFD studies showed signiﬁcantly higher body
weights for the PMI-5011–fed mice. Data are shown as means  SE (*P < 0.05).
O. ILNYTSKA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 103siRNA showed that Klf4 is required for the upregulation of
Agrp by PMI-5011.
Two candidate CACCC-boxes at positions 163/169
and 277/283 on the AGRP promoter were studied, but
only the proximal box was found to be a functional
binding site for KLF4. Subsequent EMSA, supershifts, and
ChIP experiments established the signiﬁcance of the prox-
imal CACCC-box for the binding of Klf4. Luciferase-
expressing transgenic mice with luciferase driven by the
AGRP promoter encompassing the KLF4-binding CACCC-
box at position 163/169 conﬁrmed in vivo the activa-
tion of the AGRP promoter by PMI-5011.
Feeding studies were performed to evaluate the effects
of PMI-5011 on Klf4/Agrp and other appetite-regulating
neuropeptides and to assess its effects on overall meta-
bolic and physiological parameters. In a study using indi-
rect calorimetry, PMI-5011 increased hypothalamic Klf4/
Agrp and stimulated food intake. The respiratory
exchange ratio and total locomotor activity were not
affected, but oxygen consumption and energy expenditure
were signiﬁcantly lower in the PMI-5011–fed group. Based
on these outcomes, one would expect the PMI-5011–fed
mice to gain body weight, but this was not the case
probably because of the short period of feeding and/or
because of the type of diet used (chow). Thus, a 24-day
feeding experiment was performed to test the hypothesis
that PMI-5011 may require additional time to confer body-
weight gain. Food intake and hypothalamic Klf4/Agrp
protein levels were again signiﬁcantly higher in the PMI-
5011–fed group, but body weight was again not affected.
We therefore examined the effects of PMI-5011 in three
previous studies that had used HFD to determine whether
a high fat content was required for PMI-5011 to affect body
weight. In all three studies, body weight was increased
consistently and data meta-analysis combining the three
studies showed statistical signiﬁcance. Food intake had
not been measured in these mice because these studies
had been set up to measure the effects of PMI-5011 on
insulin sensitivity under severe obesigenic conditions (35).
These data show that hypothalamic increases in Klf4 and
Agrp by PMI-5011 can lead to increased food intake but
body weight is affected only under HFD.
We also found that PMI-5011 reduced the circulating
levels of insulin and leptin that are known inhibitors of
hypothalamic Agrp (36). The gut-secreted glucagon-like
peptide 1 (GLP-1) is also affected by tarragon (20),
whereas PMI-5011 has antidiabetic effects (20), and, im-
portantly, it attenuates expression of protein tyrosine
phosphatase 1B (PTP-1B) (35). Attenuation or deletion of
PTP-1B confers resistance to body-weight gain (37), and
we speculate that our mice did not gain signiﬁcantly in
body weight by PMI-5011 because of peripheral reduction
in PTP-1B (that was not measured in our experiments).
These multifaceted effects of PMI-5011 could be because
of one or more of its six components (22). Each compo-
nent (or several of them in concert) could thus have
speciﬁc or pleiotropic effects on metabolic processes,
perhaps by crossing the blood brain barrier, and/or by
modulating peripheral hormones like insulin and leptin.
The complex effects of PMI-5011 are further under-
scored by the fact that Orexin and Mch were also upregu-
lated, whereas the anorexigenic Pomc and Cart were not
signiﬁcantly affected. It merits further investigation to
determine whether Klf4 is the mediating transcription
factor that activates Orexin and Mch that express in
different neurons. By algorithmic analysis, we found that
Orexin has a CACCC-box in its minimal promoter, but we
do not know if it is functional. We did not ﬁnd a putative
CACCC-box on the Mch promoter, but Klf4 interacts with
SP1 (30), and it could use SP1 binding sites on these two
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PMI-5011 affects the expression levels of multiple orexi-
genic neuropeptides in a complex fashion that may extend
beyond Klf4 and involve other transcription factors and
perhaps the hypothalamic receptors of peripheral hor-
mones that are also affected by PMI-5011 (e.g., insulin,
leptin).
The data presented here identify Klf4 as a major trans-
activator of Agrp. In addition, we report that the tarragon
extract PMI-5011 has complex metabolic effects that in-
clude an increase in hypothalamic Klf4 and food intake,
activation of multiple components of the orexigenic cir-
cuitry (i.e., Agrp, Mch, Orexin), and reduction of insulin
and leptin circulating levels. Klf4 is typically downregu-
lated in colorectal cancers (13,17,38,39) and has anticarci-
nogenic properties when normally expressed (21). PMI-
5011 could thus be used for enhancing Klf4 and appetite in
conditions like anorexia and cancer cachexia.
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